Related Experiment Video
Updated: Jul 14, 2025

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition
Mitsuo Terada1, Aki Ito2, Yuichiro Kikawa3
1Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Abstract:
The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment of breast cancer were updated to the 2022 edition through a process started in 2018. The updated guidelines consist of 12 background questions (BQs), 33 clinical questions (CQs), and 20 future research questions (FRQs). Multiple outcomes including efficacy and safety were selected in each CQ, and then quantitative and qualitative systematic reviews were conducted to determine the strength of evidence and strength of recommendation, which was finally determined through a voting process among designated committee members. Here, we describe eight selected CQs as important updates from the previous guidelines, including novel practice-changing updates, and recommendations based on evidence that has emerged specifically from Japanese clinical trials.
Insights
The 2022 Japanese Breast Cancer Society guidelines offer updated systemic treatment recommendations. These evidence-based updates focus on efficacy and safety, incorporating findings from Japanese clinical trials.
Area of Science:
- Oncology
- Clinical Practice Guidelines
- Breast Cancer Treatment
Background:
- The Japanese Breast Cancer Society (JBCS) initiated an update process in 2018.
- Guidelines are crucial for standardizing breast cancer care.
Purpose of the Study:
- To present the 2022 edition of the JBCS Clinical Practice Guidelines for systemic breast cancer treatment.
- To highlight key updates and practice-changing recommendations based on recent evidence.
Main Methods:
- Systematic reviews (quantitative and qualitative) of evidence were conducted for 33 clinical questions (CQs).
- Outcomes including efficacy and safety were assessed.
- Recommendations were finalized through a voting process by committee members.
Main Results:
- The 2022 guidelines include 12 background questions (BQs), 33 CQs, and 20 future research questions (FRQs).
- Eight selected CQs represent significant updates, including novel practice-changing information.
- Recommendations are based on evidence, with a focus on Japanese clinical trials.
Conclusions:
- The updated guidelines provide current, evidence-based recommendations for systemic breast cancer treatment.
- These guidelines incorporate recent advancements and trial data, particularly from Japan.
- The JBCS aims to improve patient outcomes through these updated clinical practice guidelines.
Related Concept Videos
Standards of Care II
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Prevention
Some...
Standards of Care I
Cancer Survival Analysis

